Log in to save to my catalogue

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy...

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_99e04455f1444be88b66a788433ed6e0

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

About this item

Full title

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Publisher

England: BioMed Central Ltd

Journal title

Journal for immunotherapy of cancer, 2019-02, Vol.7 (1), p.38-14, Article 38

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 (CV9202) is an active cancer immunotherapeutic comprising protamine-formulated, sequence-optimized mRNA encoding six non-small cell lung cancer (NSCLC)-associated antigens (NY-ESO-1, MAGE...

Alternative Titles

Full title

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_99e04455f1444be88b66a788433ed6e0

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_99e04455f1444be88b66a788433ed6e0

Other Identifiers

ISSN

2051-1426

E-ISSN

2051-1426

DOI

10.1186/s40425-019-0520-5

How to access this item